Cite

HARVARD Citation

    Xu, J. et al. (n.d.). 79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC). Journal for immunotherapy of cancer. p. A86. [Online]. 
  
Back to record